NCT04964609 is a NA clinical trial of EmbracePlus in Oximetry, sponsored by Empatica, Inc..

Who is sponsoring NCT04964609?

NCT04964609 is sponsored by Empatica, Inc..

What drugs are being tested in NCT04964609?

Interventions in NCT04964609: EmbracePlus.

Is NCT04964609 still recruiting?

NCT04964609 is currently completed. Last updated 25 November 2022.

Last reviewed 2022-11-25 · How we verify

NCT04964609

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EmbracePlus SpO2 Accuracy Validation

Completed NA Last updated 25 November 2022

What this trial tests

NA trial testing EmbracePlus in Oximetry in 14 participants. Completed in 21 November 2022.

Timeline

16 June 2021

Primary endpoint
21 November 2022

21 November 2022

Quick facts

Lead sponsor	Empatica, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	14
Start date	16 June 2021
Primary completion	21 November 2022
Estimated completion	21 November 2022
Sites	1 location across United States

Drugs / interventions tested

EmbracePlus

Conditions studied

Oximetry — all drugs for Oximetry →

Sponsor

Empatica, Inc.

Who can join

Adults 18 to 55, any sex, with Oximetry. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to test the accuracy of EmbracePlus computed SpO2 during mild, moderate and severe hypoxia (a lower-than-normal concentration of oxygen in arterial blood); ie, a range of arterial HbO2 saturations from 100 to down to 70%. This is done by comparing the reading of the the subject device during brief, steady state hypoxia with a gold-standard measurement of blood oxyhemoglobin (hemoglobin carrying oxygen) saturation, that is arterial blood sample processed in a laboratory.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Empatica, Inc. trials

Trials by the same sponsor.

NCT04807608 — EmbracePlus, Care App and Aura Usability Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04964609 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Empatica, Inc.
Last refreshed: 25 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04964609.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing